Clinical trials: Thiotepa
Ganglioneuroblastoma, High Risk Neuroblastoma
Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
This phase II pilot trial studies the side effects and how well dinutuximab and sargramostim work when combined with chemotherapy in patients with high-risk neuroblastoma.
- Trial name
- NCT03786783
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cisplatin
- Where
- 10 sites in United States, Australia and 1 more
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Sickle Cell Disease
Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease
The purpose of this study it to evaluate a reduced toxicity conditioning regimen for haploidentical donor HCT followed by a GVHD prophylaxis regimen comprising of post-transplant cyclophosphamide, sirolimus and abatacept with the…
- Trial name
- NCT07616154
- Testing
- Cyclophosphamide 50mg, Abatacept, Alemtuzumab
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- St. Jude Children's Research Hospital
Metastatic, Cerebral Primitive Neuroectodermal Tumors
Treatment of High-Risk Cerebral Primitive Neuroectodermal Tumors in Children Aged Over 5 Years
Primary objective : To increase the 3 year progression-free survival from 40% to 60%. Patients included : metastatic, cerebral primitive neuroectodermal tumors in children aged over 5 years.
- Trial name
- NCT00936156
- Testing
- Chemotherapy (carboplatin, etoposide, thiotepa)
- Where
- France
- Volunteers
- 68 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS
The purpose of this study is to compare safety and efficacy of reduced-intensity conditioning and myeloablative conditioning regimens prior to HSCT in high-risk AML/MDS pediatric and young adult patients.
- Conditions
- Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Hematopoietic Stem Cell Transplant (HSCT)
- Trial name
- NCT02626715
- Testing
- Reduced-Intensity Conditioning Regimen, Myeloablative Conditioning Regimen
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Randy Windreich
Severe Sickle Cell Disease, Bone Marrow Failure Syndromes
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
This study is designed to estimate the efficacy and toxicity of familial HLA mismatched bone marrow transplants in patients with non-malignant disease who are less than 21 years of age and could benefit from the procedure.
- Conditions
- Severe Sickle Cell Disease, Bone Marrow Failure Syndromes, Metabolic Disorders, Immunologic Disorders
- Trial name
- FAM BMT (NCT03128996)
- Testing
- RIC regimen, GVHD prophylaxis regimen
- Where
- 4 sites in United States
- Volunteers
- 29 people
- Sponsor
- Washington University School of Medicine
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD
This phase II trial is for patients with acute lymphocytic leukemia, acute myeloid leukemia, myelodysplastic syndrome or chronic myeloid leukemia who have been referred for a peripheral blood stem cell transplantation to treat…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Undifferentiated Leukemia
- Trial name
- NCT02220985
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine Phosphate
- Where
- 2 sites in United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Chronic Myeloproliferative Disorders, Leukemia
Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00104975
- Testing
- alemtuzumab, therapeutic allogeneic lymphocytes, fludarabine phosphate
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Yale University
Metabolic Disorders, Hematologic, Immune, or Bone Marrow Disorders
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
The hypothesis for this study is that a preparative regimen that maximizes host immunosuppression without myeloablation will be well tolerated and sufficient for engraftment of donor hematopoietic cells.
- Conditions
- Metabolic Disorders, Hematologic, Immune, or Bone Marrow Disorders, Hemoglobinopathies, Non-malignant Disorders
- Trial name
- NCT00920972
- Testing
- Treatment Plan 1: Stratum 1, Treatment Plan 2: Strata 2, 3, or 4, GVHD Regimen A: UCB Recipients
- Where
- 28 sites in United States, Canada
- Volunteers
- 220 people
- Sponsor
- Washington University School of Medicine
AML, Childhood, Aml
Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML
This trial represents a single institution phase I/II pilot study with the primary objective of establishing the safety and feasibility of generating and infusing ML NK cells after TCRαβ haplo-HCT.
- Conditions
- AML, Childhood, Aml, Acute Myeloid Leukemia, Pediatric, Acute Myeloid Leukemia
- Trial name
- ABCD-NK (NCT06158828)
- Testing
- Rabbit Anti thymocyte globulin, Busulfan, Fludarabine
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Washington University School of Medicine
Stem Cell Transplantation, Leukemia
Infusion of Expanded Cord Blood T Cells
The goal of this clinical research study is to learn if treating umbilical cord blood with growth factors before a transplant can help to improve the body's ability to accept the cord blood transplants.
- Conditions
- Stem Cell Transplantation, Leukemia, Lymphoma, Pediatric Disorders
- Trial name
- NCT00972101
- Testing
- Total Body Irradiation (TBI), Melphalan, Thiotepa
- Sponsor
- M.D. Anderson Cancer Center
Lymphoblastic Leukemia, Acute, Childhood;
ALL-SCT BFM International- HSCT in Children and Adolescents With ALL
With this protocol the ALL-SCT BFM international study group wants to evaluate whether hematopoietic stem cell transplantation (HSCT) from matched family or unrelated donors (MD) is equivalent to the HSCT from matched sibling…
- Trial name
- ALL-SCT-BFMi (NCT01423500)
- Testing
- VP16, TBI, VP16, ATG
- Where
- 24 sites in Austria, Czechia and 9 more
- Volunteers
- 405 people
- Sponsor
- St. Anna Kinderkrebsforschung
Acute Myeloid Leukemia, Adult
Up-front Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients Aged 65-75
Patients with acute myeloid leukemia aged 65-75 have a very poor prognosis, irrespective of the treatment strategy, including demethylating agents or conventional chemotherapy.
- Trial name
- NCT03902665
- Testing
- Up-front allogeneic hematopoietic stem cell transplantation (HSCT)
- Where
- Italy
- Volunteers
- 19 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Breast Cancer
Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer
Investigator-initiated, international, multicentre, randomized, open-label, (neo)adjuvant phase III study in target population (stage III, HER2-negative, BRCA1-like breast cancer patients) comparing optimized standard-dose…
- Trial name
- Subito (NCT02810743)
- Testing
- ddAC-CP-Olaparib, ddAC-mini CTC
- Where
- 11 sites in France, Netherlands
- Volunteers
- 174 people
- Sponsor
- The Netherlands Cancer Institute
Extragonadal Germ Cell Tumor, Ovarian Cancer
Combination Chemotherapy Followed by Bone Marrow or Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Germ Cell Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow doctors to give higher doses of chemotherapy and kill more…
- Conditions
- Extragonadal Germ Cell Tumor, Ovarian Cancer, Testicular Germ Cell Tumor
- Trial name
- NCT00002508
- Testing
- carboplatin, etoposide, autologous bone marrow transplantation
- Where
- United States
- Sponsor
- Temple University
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Biological Therapy in Treating Patients With Solid Tumors or Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Conditions
- Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00027937
- Testing
- aldesleukin, filgrastim, sargramostim
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Osteosarcoma
Adjuvant High-Dose Thiotepa and Stem Cell Rescue Associated With Conventional Chemotherapy in Relapsed Osteosarcoma
Approximately 150 new cases of osteosarcoma are reported each year in France, of which 15 to 20% are metastatic. Further to the initial standard care, about 45% of the patients relapse within a median duration of 20 months.
- Trial name
- OSII-TTP (NCT00978471)
- Testing
- Thiotepa
- Where
- 23 sites in France
- Volunteers
- 44 people
- Sponsor
- Centre Leon Berard
Chronic Myeloproliferative Disorders, Leukemia
Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia
RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral stem cell transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic/Myeloproliferative Diseases
- Trial name
- NCT00066417
- Testing
- cyclophosphamide, cyclosporine, fludarabine phosphate
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Central Nervous System Nongerminomatous Germ Cell Tumor, Choriocarcinoma
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not…
- Conditions
- Central Nervous System Nongerminomatous Germ Cell Tumor, Choriocarcinoma, Embryonal Carcinoma, Immature Teratoma
- Trial name
- NCT04684368
- Testing
- Biospecimen Collection, Carboplatin, Etoposide
- Where
- 170 sites in United States, Australia and 2 more
- Volunteers
- 160 people
- Sponsor
- Children's Oncology Group
Adult Acute Erythroid Leukemia, Adult Acute Monoblastic and Acute Monocytic Leukemia
Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission
RATIONALE: A peripheral stem cell transplant may be able to replace blood-forming cells that were destroyed by chemotherapy or radiation therapy.
- Conditions
- Adult Acute Erythroid Leukemia, Adult Acute Monoblastic and Acute Monocytic Leukemia, Adult Acute Myeloid Leukemia
- Trial name
- NCT00101140
- Testing
- anti-thymocyte globulin, fludarabine phosphate, thiotepa
- Sponsor
- Eastern Cooperative Oncology Group
High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
This is an international multicenter, open-label, randomized phase III trial including three sequential randomizations to assess efficacy of induction and consolidation chemotherapies and radiotherapy for patients with high-risk…
- Trial name
- HR-NBL2 (NCT04221035)
- Testing
- Vincristine, Carboplatin, Etoposide
- Where
- 142 sites in Australia, Austria and 18 more
- Volunteers
- 800 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris